Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Safety of Lumiracoxib in Patients With Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00637949
Recruitment Status : Completed
First Posted : March 18, 2008
Last Update Posted : March 18, 2008
Information provided by:

Brief Summary:
This safety study evaluated the incidence of gastrointestinal adverse events and edema in patients with osteoarthritis treated with lumiracoxib and rofecoxib as comparator

Condition or disease Intervention/treatment Phase
Osteoarthritis Device: lumiracoxib Drug: rofecoxib Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 309 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated With COX189 400 mg o-do Using Rofecoxib 25 mg o.d. as a Comparator
Study Start Date : December 2000
Actual Primary Completion Date : March 2001
Actual Study Completion Date : March 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: 1 Device: lumiracoxib
400 mg once daily, oral over 6 weeks
Other Name: Prexige

Active Comparator: 2 Drug: rofecoxib
25 mg, oral, daily over 6 weeks
Other Name: Vioxx

Primary Outcome Measures :
  1. Incidence of at least one of seven predefined gastrointestinal adverse events [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >=50 years old
  • Primary osteoarthritis in hip, hand, knee or spine for at least 3 month
  • Pain in the target joint of moderate intensity
  • Written informed consent

Exclusion Criteria:

  • Secondary osteoarthritis
  • Active upper gastro intestinal tract ulceration
  • Inflammatory joint disease
  • Gout
  • Clinically significant hepatic or renal disease

Other in and exclusion criteria may apply

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: External Affairs, Novartis Identifier: NCT00637949    
Other Study ID Numbers: CCOX189A2307
First Posted: March 18, 2008    Key Record Dates
Last Update Posted: March 18, 2008
Last Verified: March 2008
Keywords provided by Novartis:
Osteoarthritis (primary osteoarthritis hip, hand, knee or spine (cervical or lumbar)
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents